Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

Asia-Pacific Journal of Clinical Oncology

Volumn 12, Issue 2, 2016, Pages e339-e346

  Liu, Lu ^a   Zhou, Fei ^a   Ren, Shengxiang ^a   Chen, Xiaoxia ^a   Li, Xuefei ^a   Li, Wei ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

chemotherapy; cyclooxygenase 2; non small cell lung cancer; platinum; polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; NAVELBINE; PACLITAXEL; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 85028267176     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12258     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69–90.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 (2): 92–98.
3. Gronberg BH, Bremnes RM, Flotten O et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27 (19): 3217–3224.
4. Tan XL, Moyer AM, Fridley BL et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2011; 17 (17): 5801–5811.
5. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15 (8): 1194–1203.
6. Ren S, Zhou S, Wu F et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 2012; 75 (1): 102–109.
7. Dixon DA. Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res 2003; 37: 52–71.
8. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24 (2): 96–102.
9. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004; 10 (12 Pt 2): 4266s–4269.
10. Ruegg C, Zaric J, Stupp R. Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Ann Med 2003; 35 (7): 476–487.
11. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996; 10 (1): 1–17.
12. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58 (22): 4997–5001.
13. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 1999; 90 (12): 1338–1343.
14. Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7 (4): 861–867.
15. Achiwa H, Yatabe Y, Hida T et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5 (5): 1001–1005.
16. Kim SH, Park HS. Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J 2006; 47 (1): 15–21.
17. Zhao D, Xu D, Zhang X et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 2009; 136 (5): 1659–1668.
18. Lukiw WJ, Bazan NG. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res 1997; 50 (6): 937–945.
19. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345 (6): 433–442.
20. Zhang X, Miao X, Tan W et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129 (2): 565–576.
21. Zhao D, Zhang X, Guo Y, Tan W, Lin D. Cyclooxygenase-2 Gly587Arg variant is associated with differential enzymatic activity and risk of esophageal squamous-cell carcinoma. Mol Carcinog 2009; 48 (10): 934–941.
22. Park JM, Choi JE, Chae MH et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006; 6: 70.
23. Piranda DN, Festa-Vasconcellos JS, Amaral LM, Bergmann A, Vianna-Jorge R. Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer 2010; 10: 613.
24. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, Gonzalez-Aguilera JJ, Fernandez-Peralta AM. Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 2009; 20 (8): 1421–1429.
25. Bi N, Yang M, Zhang L et al. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res 2010; 16 (8): 2383–2390.
26. Zhang L, Gao G, Li X et al. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS ONE 2012; 7 (10): e48350.
27. Zhou F, Gao G, Ren S, Li X, He Y, Zhou C. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy. PLoS ONE 2013; 8 (4): e61585.
28. Tan W, Wu J, Zhang X et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007; 28 (6): 1197–1201.
29. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008; 75 (4): 380–385.
30. Edelman MJ, Watson D, Wang X et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy – Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008; 26 (6): 848–855.
31. Schneider BJ, Kalemkerian GP, Kraut MJ et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol 2008; 3 (12): 1454–1459.
32. Mutter R, Lu B, Carbone DP et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009; 15 (6): 2158–2165.
33. Groen HJ, Sietsma H, Vincent A et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol 2011; 29 (32): 4320–4326.
34. Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013; 19 (8): 1941–1948.
35. Eng L, Su J, Qiu X et al. Second-hand smoke as a predictor of smoking cessation among lung cancer survivors. J Clin Oncol 2014; 32 (6): 564–570.